Glioma
Conditions
Interventions
Observation group:None
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Participants must meet all of the following criteria to be enrolled: 1. Diagnostic criteria: clinically or pathologically diagnosed with glioma, preliminarily diagnosed by imaging (CT/MRI) as having glioma, scheduled for surgical treatment with postoperative pathology available for definitive diagnosis; 2. Demographic criteria: age 18–70 years, no restrictions on gender or ethnicity; 3. Treatment history requirements: no prior radiotherapy or chemotherapy before imaging, no surgical resection (including partial resection), and no prior targeted therapy or immunotherapy; 4. Imaging requirements: no significant head motion or artifacts on MRI images, and ability to cooperate to complete all MRI sequences; 5. Informed consent: full legal capacity, ability to understand the study content and voluntarily sign the informed consent form, and willingness to comply with all requirements of the study protocol.
Exclusion criteria
Exclusion criteria: Participants who meet any of the following criteria shall be excluded from the study: 1. Disease-related: History of other intracranial tumors; concomitant central nervous system diseases (such as multiple sclerosis, epilepsy, etc.); presence of intracranial infection, cerebral hemorrhage, cerebral infarction, or other intracranial lesions; 2. Systemic diseases: Concomitant severe cardiac diseases (e.g., cardiac insufficiency NYHA Class III–IV, severe arrhythmia, etc.); hepatic or renal dysfunction (transaminase > 3 times the upper limit of normal / creatinine clearance rate < 30 mL/min); psychiatric disorders (such as schizophrenia, major depression, etc.); other systemic diseases considered by the investigator to be unsuitable for clinical research; 3. MRI contraindications: Presence of claustrophobia or inability to undergo MRI examination; implanted MRI-incompatible devices (e.g., cardiac pacemakers, metal clips, cochlear implants, etc.); history of allergy to gadolinium-based contrast agents; pregnant or lactating women; 4. Study-related: Current participation in other clinical research; participation in other drug clinical trials within the last 3 months; poor MRI image quality likely to affect subsequent analysis; inability to understand the study content or poor compliance; other circumstances deemed by the investigator to be unsuitable for study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in diffusion-relaxation spectrum signal fractions between low-grade and high-grade patients;Correlation of diffusion-relaxation spectrum signal fraction and glioma molecular phenotype; | — |
Countries
China
Contacts
Public ContactRong Lu
Huashan Hospital, Fudan University
Outcome results
None listed